Markets falter ahead of voting on US healthcare legislation
For the best part, global markets remained in a holding pattern awaiting the outcome of the House of Representatives vote on healthcare or ‘Trumpcare’ legislation, an important component of the Trump administration’s election win, and now a litmus test of whether the new government will be able to make the fiscal changes it has promised.
While there are different schools of thought as to whether the legislation will pass, markets appear to be getting increasingly pessimistic. The CBOE Volatility Index (VIX), commonly referred to as the ‘fear gauge’ increased 2.4% to its highest level in 2017.
Though the Dow was up approximately 100 points mid-session, all of those gains were lost plus some, as robust selling emerged in the last hour of trading.
It was also the last hour’s trading that brought the NASDAQ undone as it closed four points lower to finish at 5817 points.
The UK was taking its lead from the US, only increasing 0.2% to 7340 points despite positive retail sales figures being released.
However, there were some solid performances on mainland Europe with the DAX and the Paris CAC 40 increasing 1.1% and 0.8% respectively to close at 12,039 points and 5032 points.
The oil price continued to come under pressure, finishing close to its intraday low of US$47.58 per barrel after trading as high as US$48.48 per barrel.
Elsewhere on the commodities front, iron ore retrieved some of its recent loss ground, increasing 1.6% to US$86.36 per tonne.
Gold broke its winning streak, finishing 0.4% lower at US$1248 per ounce.
Base metals were mixed with copper up 0.8% and zinc coming off 1.1%. Nickel and lead were flat.
The Australian dollar is fetching US$0.763.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.